Accessibility Menu
Scorpius logo

Scorpius

(NYSEMKT) HTBX

This security has been delisted. This page is retained for historical reference.

Scorpius last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-17
Scorpius stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-45.45%USD 0.002026-07-10
1 month+9.09%USD 0.002026-06-17
3 month-88%USD 0.012026-04-17
Year to date+500%USD 0.002025-12-31
1 year-98.63%USD 0.092025-07-17
3 year-100%USD 142.002023-07-18
5 year-100%USD 1,232.002021-07-16
Since inception-100%USD 133,980.132013-07-24

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

HTBX Financials

Key Financial Metrics (TTM)

Gross Margin

23.00%

Operating Margin

-1087.02%

Net Income Margin

-2378.34%

Return on Equity

35.52%

Return on Capital

-31.15%

Return on Assets

-29.54%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$3.05T

Operating Income

-$34.33T

EBITDA

-$4.87T

Operating Cash Flow

-$32.78T

Capital Expenditure

-$932.87B

Free Cash Flow

-$36.63T

Cash & ST Invst.

$60.08M

Total Debt

$18.12T

Scorpius Performance Analysis

Scorpius annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 2,112,806N/A
20222022-12-31USD 370,176-82.5%
20232023-12-31USD 6,994,8381789.6%
20242024-12-31USD 6,243,022-10.7%
Scorpius sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31-100.0%
Q22025-06-30-89.3%
Q32025-09-301.0%
Scorpius annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -281.54N/A
20222022-12-31USD -339.2520.5%
20232023-12-31USD -347.202.3%
20242024-12-31USD -13.04-96.2%
Scorpius sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-3190.2%
Q22025-06-3092.2%
Q32025-09-3077.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$229.84K

+8.2%

Gross Profit

$844.72K

+297.7%

Gross Margin

3.68%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

49

N/A

Net Income

-$9.84M

-18.5%

EBITDA

$1.42T

+18053442.7%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$60.08M

-28.6%

Total Debt

$18.12T

+877369747.7%

Accounts Receivable

$179.89K

+80.4%

Inventory

$203.48B

N/A

Long Term Debt

$5.51M

+293.3%

Short Term Debt

$12.61T

+1897153323.8%

Return on Assets

-29.54%

N/A

Return on Invested Capital

0.00%

N/A

Free Cash Flow

-$2.92T

-25804629.4%

Operating Cash Flow

-$29.17M

-185.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACHLAchilles Therapeutics plc
$1.48+0.68%
RPHMReneo Pharmaceuticals, Inc.
$18.20+952.02%
TCRRTCR2 Therapeutics Inc.
$1.48+0.00%
SGTXSigilon Therapeutics, Inc.
$22.47-2.56%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
INTCIntel
$95.04-0.02%
NOKNokia
$10.12-0.03%
PATHUiPath
$12.15+0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.